tiprankstipranks
Trending News
More News >
JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
Japanese Market

JCR Pharmaceuticals Co., Ltd. (4552) Price & Analysis

Compare
1 Followers

4552 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

1.33%97.60%
Insiders
1.33%
Mutual Funds
― Other Institutional Investors
97.60% Public Companies and
Individual Investors

4552 FAQ

What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥386.00 and its highest was ¥765.00 in the past 12 months.
    What is JCR Pharmaceuticals Co., Ltd.’s market cap?
    JCR Pharmaceuticals Co., Ltd.’s market cap is ¥55.81B.
      When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
      JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 23, 2025 which is in 60 days.
        How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
        JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2025. The company reported -¥33.8 earnings per share for the quarter, beating the consensus estimate of -¥53.704 by ¥19.904.
          Is JCR Pharmaceuticals Co., Ltd. overvalued?
          According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does JCR Pharmaceuticals Co., Ltd. pay dividends?
            JCR Pharmaceuticals Co., Ltd. pays a Annually dividend of ¥20 which represents an annual dividend yield of 4.37%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
              What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
              JCR Pharmaceuticals Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
              JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
                What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
                JCR Pharmaceuticals Co., Ltd. reported an EPS of -¥33.8 in its last earnings report, beating expectations of -¥53.704. Following the earnings report the stock price went up 2.972%.
                  Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
                  Currently, no hedge funds are holding shares in JP:4552

                  Company Description

                  JCR Pharmaceuticals Co., Ltd.

                  JCR Pharmaceuticals Co., Ltd. is a Japan-based company engaged in the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes particularly in biopharmaceuticals, with a focus on enzyme replacement therapies and therapeutic proteins aimed at treating rare diseases. JCR is noted for its innovative drug delivery systems, as well as its commitment to improving patient outcomes through cutting-edge biotechnology solutions.

                  4552 Stock 12 Month Forecast

                  Average Price Target

                  ¥600.00
                  ▲( 31.00% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"496":"¥496","626":"¥626","756":"¥756","886":"¥886","1016":"¥1,016"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥600.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[496,626,756,886,1016],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Oct<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497,504.9230769230769,512.8461538461538,520.7692307692307,528.6923076923077,536.6153846153846,544.5384615384615,552.4615384615385,560.3846153846154,568.3076923076923,576.2307692307693,584.1538461538462,592.0769230769231,{"y":600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497,504.9230769230769,512.8461538461538,520.7692307692307,528.6923076923077,536.6153846153846,544.5384615384615,552.4615384615385,560.3846153846154,568.3076923076923,576.2307692307693,584.1538461538462,592.0769230769231,{"y":600,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,497,504.9230769230769,512.8461538461538,520.7692307692307,528.6923076923077,536.6153846153846,544.5384615384615,552.4615384615385,560.3846153846154,568.3076923076923,576.2307692307693,584.1538461538462,592.0769230769231,{"y":600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1015.77,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":856.04,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":812.75,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":786.63,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":555.38,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":594.08,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":550.54,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":592.15,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":592.15,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":648.94,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":595.92,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":542.91,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":497,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Astellas Pharma
                  Chugai Pharmaceutical Co
                  Shionogi & Co
                  Eisai Co
                  Takeda Pharmaceutical Co
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis